Palbociclib in advanced breast cancer: Disadvantages predominate in certain patients

(Institute for Quality and Efficiency in Health Care) More severe side effects occur under the combination of palbociclib and letrozole in the first-line treatment of postmenopausal women. Data were lacking for other patient groups.